Why the study?
Is peri-operative statin therapy cost-effective in patients undergoing major elective vascular surgery?
Is peri-operative statin therapy cost-effective in patients undergoing major elective vascular surgery?
Peri-operative statin therapy for major vascular surgery appears highly cost-effective, recovering nearly 60% of drug costs by reducing adverse events.
Answers are grounded in this paper and cite their sources.
May support cost-effective peri-operative statin use in vascular surgery; leaves open confirmation by randomized trials.
We analysed the pharmaco-economics of the prospective peri-operative studies of statin administration for major elective vascular surgery, using the NHS reference costs for 2004. This analysis suggests that peri-operative statin therapy for patients undergoing vascular surgery may present the most cost-effective use of statin therapy yet described, with a number-needed-to-treat of 15 and almost 60% of the total cost of atorvastatin therapy recovered through a reduction in peri-operative adverse events.
No takes yet. Share an insight, caveat, or question.
Biccard et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: